NCT05978141 A Registry for People With T-cell Lymphoma
| NCT ID | NCT05978141 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Condition | T-cell Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2023-07-27 |
| Primary Completion | 2030-07-27 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2023-07-27 with a primary completion date of 2030-07-27.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.
Eligibility Criteria
Inclusion Criteria: * Written informed consent * Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy. * Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of the following diagnostic criterion (based on WHO classification and NCCN guidelines): * T-cell prolymphocytic leukemia * T-cell large granular lymphocytic leukemia * Chronic lymphoproliferative disorder of NK cells * Aggressive NK-cell leukemia * Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood * Chronic active EBV infection of T- and NK-cell type, systemic form * Hydroa vacciniforme-like lymphoproliferative disorder * Adult T-cell leukemia/lymphoma * Extranodal NK/T-cell lymphoma, nasal type * Enteropathy-associated T-cell lymphoma * Monomorphic epitheliotropic intestinal T-cell lymphoma * Intestinal T-cell lymphoma, not otherwise specified (NOS) * Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract * Hepatosplenic T-cell lymphoma * Subcutaneous panniculitis-like T-cell lymphoma * Mycosis fungoides (limited to those with ≥ stage IB disease and those receiving active therapy) * Sézary syndrome * Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy) * Primary cutaneous Gamma-Delta T-cell lymphoma * Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma * Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy) * Peripheral T-cell lymphoma, not otherwise specified * Angioimmunoblastic T-cell lymphoma * Follicular T-cell lymphoma * Nodal peripheral T-cell lymphoma with TFH phenotype * Anaplastic large cell lymphoma, ALK-positive * Anaplastic large cell lymphoma, ALK-negative * Breast-implant associated anaplastic large cell lymphoma. * NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma must be receiving systemic therapy. Exclusion Criteria: * Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma not receiving systemic therapy. * Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.
Contact & Investigator
Steven Horwitz, MD
PRINCIPAL INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Frequently Asked Questions
Who can join the NCT05978141 clinical trial?
This trial is open to participants of all sexes, studying T-cell Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05978141 currently recruiting?
Yes, NCT05978141 is actively recruiting participants. Contact the research team at horwitzs@MSKCC.ORG for enrollment information.
Where is the NCT05978141 trial being conducted?
This trial is being conducted at Duarte, United States, San Diego, United States, San Francisco, United States, Stanford, United States and 11 additional locations.
Who is sponsoring the NCT05978141 clinical trial?
NCT05978141 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is Steven Horwitz, MD at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 1,000 participants.